Stiefel, Basilea sign agreement for Toctino
Toctino is used to treat adults with severe chronic hand eczema that is refractory to treatment with potent topical corticosteroids. Under the agreement Stiefel will be responsible for
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
The research collaboration will focus on three neglected tropical diseases (NTDs), leishmaniasis, Chagas disease, and sleeping sickness. Astellas drug discovery research senior vice president Shin-ichi Tsukamoto said the